Dr. Gurbani received his Ph.D in biotechnology from the Council of Scientific & Industrial Research (CSIR) -Institute of Toxicology Research, Lucknow and Jamia Hamdard University, New Delhi, India, with an emphasis on molecular mechanism of quinone-based DNA damage and repair. His work demonstrated quinone inhibition of ATPase domain movement during the catalytic cycle of topoisomerase IIα resulting in inhibition of DNA repair and loss of genomic integrity, which may result in clastogenicity and leukemia.

During his postdoctoral training (2012-2018) in Westover Lab, part of the Department of Radiation Oncology at UT Southwestern, Dr. Gurbani led experimental efforts toward the development of several reversible and irreversible inhibitors for different cancer-associated kinases serving as useful pharmacological probes. During this period, Dr. Gurbani also completed coursework in clinical pharmacology and drug development.

Dr. Gurbani was promoted to Instructor on February 1, 2019. With his expertise in X-ray crystallography, biochemistry, cancer biology, and structure-guided drug development, Dr. Deepak continues to develop lead compounds targeting other cancer-associated kinases for development of new targeted cancer therapies.

Research Interest

  • Cancer therapeutics: developing kinase inhibitors
  • Developing RAS inhibitors
  • DNA damage and repair
  • Protein: structure and function


Featured Publications LegendFeatured Publications

Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome.
Rao S, Gurbani D, Du G, Everley RA, Browne CM, Chaikuad A, Li T, Schröder M, Gondi S, Ficarro SB, Sim T, Kim ND, Berberich MJ, Knapp S, Marto JA, Westover KD, Sorger PK, Gray NS, Cell Chem Biol 2019 Mar
Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-a Inhibition for Cancer and Autoimmune Disease.
Totzke J, Gurbani D, Raphemot R, Hughes PF, Bodoor K, Carlson DA, Loiselle DR, Bera AK, Eibschutz LS, Perkins MM, Eubanks AL, Campbell PL, Fox DA, Westover KD, Haystead TAJ, Derbyshire ER Cell Chem Biol 2017 Aug 24 8 1029-1039.e7
MicroRNA-218 functions as a tumor suppressor in lung cancer by targeting IL-6/STAT3 and negatively correlates with poor prognosis.
Yang Y, Ding L, Hu Q, Xia J, Sun J, Wang X, Xiong H, Gurbani D, Li L, Liu Y, Liu A Mol. Cancer 2017 08 16 1 141
Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors.
Tan L, Gurbani D, Weisberg EL, Jones DS, Rao S, Singer WD, Bernard FM, Mowafy S, Jenney A, Du G, Nonami A, Griffin JD, Lauffenburger DA, Westover KD, Sorger PK, Gray NS Bioorg. Med. Chem. 2017 02 25 4 1320-1328
Structure-guided development of covalent TAK1 inhibitors.
Tan L, Gurbani D, Weisberg EL, Hunter JC, Li L, Jones DS, Ficarro SB, Mowafy S, Tam CP, Rao S, Du G, Griffin JD, Sorger PK, Marto JA, Westover KD, Gray NS Bioorg. Med. Chem. 2017 02 25 3 838-846
Structural and Biochemical Analyses Reveal the Mechanism of Glutathione S-Transferase Pi 1 Inhibition by the Anti-cancer Compound Piperlongumine.
Harshbarger W, Gondi S, Ficarro SB, Hunter J, Udayakumar D, Gurbani D, Singer WD, Liu Y, Li L, Marto JA, Westover KD J. Biol. Chem. 2017 Jan 292 1 112-120
Structural dataset for the fast-exchanging KRAS G13D.
Lu J, Hunter J, Manandhar A, Gurbani D, Westover KD Data Brief 2015 Dec 5 572-8
Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations.
Hunter JC, Manandhar A, Carrasco MA, Gurbani D, Gondi S, Westover KD Mol. Cancer Res. 2015 Sep 13 9 1325-35
Development of small molecules targeting the pseudokinase Her3.
Lim SM, Xie T, Westover KD, Ficarro SB, Tae HS, Gurbani D, Sim T, Marto JA, Jänne PA, Crews CM, Gray NS Bioorg. Med. Chem. Lett. 2015 Aug 25 16 3382-9
Discovery of type II inhibitors of TGFß-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2).
Tan L, Nomanbhoy T, Gurbani D, Patricelli M, Hunter J, Geng J, Herhaus L, Zhang J, Pauls E, Ham Y, Choi HG, Xie T, Deng X, Buhrlage SJ, Sim T, Cohen P, Sapkota G, Westover KD, Gray NS J. Med. Chem. 2015 Jan 58 1 183-96

Honors & Awards

  • PDA Travel Award, UT Southwestern Medical Center, Dallas, Texas, US
  • RCB-Young Investigator (RCB-YI) Award, Regional Centre for Biotechnology, India
  • International Travel Award, Department of Science & Technology, India
  • International Travel Award, Department of Science & Technology, India
  • Junior Research Fellowship in Life Sciences, Council of Scientific and Industrial Research, India
  • Junior Research Fellowship, Indian Council of Medical Research, India
  • Lectureship Award in Life Sciences, University Grants Commission, India

Professional Associations/Affiliations

  • American Association for Cancer Research (2017)
  • American Association for the Advancement of Science (2017)
  • American Cancer Society Cancer Action Network (2017)
  • Radiation Research Society (2014)
  • Indian Nanoscience Society (2007)